Evaluation of Expression of LRBA and CTLA-4 Proteins in Common Variable Immunodeficiency Patients
Common variable immunodeficiency (CVID) is a primary immunodeficiency disease with a heterogeneous genetic background. Lipopolysaccharide-responsive beige-like anchor (LRBA), as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have important regulatory roles in the immune responses. Here, we have investigated the expression of LRBA and CTLA-4 proteins in CVID patients with at least one presentation of early-onset occurrence, autoimmunity, or enteropathy. In this study, 20 newly diagnosed CVID patients without infection only phenotype, and ten healthy individuals were enrolled. The expressions of LRBA and CTLA-4 proteins were assessed by western blotting and flow cytometry, respectively. The patients were divided into two groups of autoimmunity-positive (11 cases) and autoimmunity-negative (9 patients). LRBA and CTLA-4 expressions were significantly lower in autoimmune-positive patients than in healthy individuals (P = .03 and P = .03, respectively). Autoimmune-negative patients had lower expression of LRBA and CTLA-4 than the control group, although it was not significant. There was a positive correlation between the expressions of LRBA and CTLA-4 in both groups of patients (P < .05). Furthermore, the highest frequency of LRBA (85.7%) and CTLA-4 (71.4%) defects was detected in those with concomitant presence of autoimmunity, enteropathy, and early-onset occurrence. Concurrent presence of autoimmunity, enteropathy, and early-onset occurrence in CVID patients could be indicative of a lack of expression in LRBA and CTLA-4 proteins. This could be helpful in early diagnosis and initiation of appropriate treatment in these patients prior to genetic confirmation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Immunological investigations - 51(2022), 2 vom: 01. Feb., Seite 381-394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salami, Fereshte [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/08820139.2020.1833029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317592351 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317592351 | ||
| 003 | DE-627 | ||
| 005 | 20231225163606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/08820139.2020.1833029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317592351 | ||
| 035 | |a (NLM)33191838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salami, Fereshte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Expression of LRBA and CTLA-4 Proteins in Common Variable Immunodeficiency Patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Common variable immunodeficiency (CVID) is a primary immunodeficiency disease with a heterogeneous genetic background. Lipopolysaccharide-responsive beige-like anchor (LRBA), as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have important regulatory roles in the immune responses. Here, we have investigated the expression of LRBA and CTLA-4 proteins in CVID patients with at least one presentation of early-onset occurrence, autoimmunity, or enteropathy. In this study, 20 newly diagnosed CVID patients without infection only phenotype, and ten healthy individuals were enrolled. The expressions of LRBA and CTLA-4 proteins were assessed by western blotting and flow cytometry, respectively. The patients were divided into two groups of autoimmunity-positive (11 cases) and autoimmunity-negative (9 patients). LRBA and CTLA-4 expressions were significantly lower in autoimmune-positive patients than in healthy individuals (P = .03 and P = .03, respectively). Autoimmune-negative patients had lower expression of LRBA and CTLA-4 than the control group, although it was not significant. There was a positive correlation between the expressions of LRBA and CTLA-4 in both groups of patients (P < .05). Furthermore, the highest frequency of LRBA (85.7%) and CTLA-4 (71.4%) defects was detected in those with concomitant presence of autoimmunity, enteropathy, and early-onset occurrence. Concurrent presence of autoimmunity, enteropathy, and early-onset occurrence in CVID patients could be indicative of a lack of expression in LRBA and CTLA-4 proteins. This could be helpful in early diagnosis and initiation of appropriate treatment in these patients prior to genetic confirmation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Common variable immunodeficiency (CVID) | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) | |
| 650 | 4 | |a early-onset occurrence | |
| 650 | 4 | |a enteropathy | |
| 650 | 4 | |a lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) | |
| 650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a CTLA4 protein, human |2 NLM | |
| 650 | 7 | |a LRBA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.- |2 NLM | |
| 700 | 1 | |a Fekrvand, Saba |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdani, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Shahkarami, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Gholamreza |e verfasserin |4 aut | |
| 700 | 1 | |a Bagheri, Yasser |e verfasserin |4 aut | |
| 700 | 1 | |a Delavari, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Shariati, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdaviani, Seyed Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Nabavi, Mohammamd |e verfasserin |4 aut | |
| 700 | 1 | |a Shirkani, Afshin |e verfasserin |4 aut | |
| 700 | 1 | |a Abolhassani, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Samadi, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Aghamohammadi, Asghar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunological investigations |d 1993 |g 51(2022), 2 vom: 01. Feb., Seite 381-394 |w (DE-627)NLM013121472 |x 1532-4311 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:381-394 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/08820139.2020.1833029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2022 |e 2 |b 01 |c 02 |h 381-394 | ||